-+ 0.00%
-+ 0.00%
-+ 0.00%

CytoDyn Advances Leronlimab Into Two Phase 1 Trials for Metastatic Triple-Negative Breast Cancer

PUBT·11/10/2026 13:34:53
Listen to the news
CytoDyn Advances Leronlimab Into Two Phase 1 Trials for Metastatic Triple-Negative Breast Cancer
  • CytoDyn will advance leronlimab into two early-stage PRE-I-SPY trials for metastatic triple-negative breast cancer, sponsored by Quantum Leap Healthcare Collaborative.
  • PRE5 will test leronlimab with Merck's pembrolizumab and sacituzumab, primarily in patients receiving first- or second-line treatment.
  • PRE7 will evaluate leronlimab with Akeso's penpulimab and chemotherapy in patients receiving second-line treatment.
  • Enrollment for PRE5 is expected in the first quarter of 2027; PRE7 enrollment is likely in the second or third quarter.
  • Results are forthcoming; the trials will assess safety, tolerability and preliminary clinical activity to help guide further development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100830PRIMZONEFULLFEED9873694) on November 10, 2026, and is solely responsible for the information contained therein.